Oral presentation | Open | Published:
Surgical issues in the breast and axillary nodes in patients treated with neoadjuvant systemic therapy
Breast Cancer Researchvolume 9, Article number: S7 (2007)
Several unique surgical issues arise in the management of patients who are candidates for neoadjuvant systemic therapy. These involve the original diagnostic assessment of the extent of disease in the breast and axilla, the preoperative planning, and ultimately the surgical management of the primary breast tumor and that of axillary lymph nodes. Careful consideration of these issues is crucial in order to maximize local control of the disease, while minimizing the extent of the required surgical resection and the ensuing surgical morbidity.
Adequate diagnostic assessment with core needle biopsy before the initiation of neoadjuvant systemic therapy ensures the presence of invasive carcinoma and provides adequate material for routine biomarker evaluation (such as ER, PR and HER-2 neu), while minimally disturbing the primary breast tumor. Consideration should also be given in assessing the status of axillary nodes by minimally invasive techniques such as ultrasound of the axilla and fine needle aspiration of suspicious nodes. Optimal preoperative planning aims at accurately determining the patterns of primary tumor shrinkage and the amount and location of any residual disease in the breast.
Surgical treatment after neoadjuvant systemic therapy focuses on the management of the primary breast tumor and that of axillary lymph nodes. Regarding the primary breast tumor, several studies have shown that neoadjuvant systemic therapy converts a proportion of mastectomy candidates to candidates for breast-conserving surgery. Neoadjuvant systemic therapy can also decrease the amount of breast tissue that needs to be removed at lumpectomy even in patients who are lumpectomy candidates at presentation.
Neoadjuvant systemic therapy (primarily neoadjuvant chemotherapy) downstages axillary lymph nodes in up to 30–40% of the patients. Although this observation was of little clinical significance when axillary node dissection was the sole method for staging the axilla, the development and validation of sentinel lymph node biopsy has provided an additional potential advantage for neoadjuvant chemotherapy; that is, the possibility of decreasing the extent and morbidity of axillary surgery. This approach is, naturally, predicated on the premise that sentinel node biopsy is feasible and accurate following neoadjuvant chemotherapy. Until recently, only small, single-institution studies have examined the efficacy of lymphatic mapping and the accuracy of sentinel node biopsy after neoadjuvant chemotherapy with significant variability in the rate of sentinel node identification and in the rate of false negative sentinel node . When these studies are examined collectively [1, 2] or when larger, multicenter data sets are analyzed , however, sentinel node biopsy after neoadjuvant chemotherapy appears to have similar performance characteristics to those of sentinel node biopsy before systemic therapy [4–6].
Some have proposed that candidates for neoadjuvant systemic therapy should have a sentinel node biopsy before, rather than after, neoadjuvant systemic therapy so that information on the status of the axillary nodes is obtained without the potential confounding effects of systemic treatment, and sentinel node-negative patients can avoid axillary dissection [7–9]. Although this approach may be useful in patients who will not need systemic therapy (that is, chemotherapy) if the sentinel node is negative, it is not generally useful for the majority of candidates for neoadjuvant systemic therapy, for whom little – if anything – is to be gained by knowing the pathologic nodal status upfront. In addition, this approach commits patients to two surgical procedures and does not take advantage of the down-staging effect of neoadjuvant chemotherapy on the axillary nodes.
Mamounas EP: Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am. 2003, 83: 931-942. 10.1016/S0039-6109(03)00032-X.
Xing Y, Ding D, Cox D, et al: Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer [abstract 561]. Proc Am Soc Clin Oncol. 2004, 23: 17-
Mamounas EP, Brown A, Anderson S, et al: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005, 23: 2694-2702. 10.1200/JCO.2005.05.188.
Veronesi U, Paganelli G, Viale G, et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003, 349: 546-553. 10.1056/NEJMoa012782.
McMasters KM, Tuttle TM, Carlson DJ, et al: Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000, 18: 2560-2566.
Krag D, Weaver D, Ashikaga T, et al: The sentinel node in breast cancer – a multicenter validation study. N Engl J Med. 1998, 339: 941-946. 10.1056/NEJM199810013391401.
Bedrosian I, Reynolds C, Mick R, et al: Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000, 88: 2540-2545. 10.1002/1097-0142(20000601)88:11<2540::AID-CNCR16>3.0.CO;2-A.
Schrenk P, Hochreiner G, Fridrik M, et al: Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003, 9: 282-287. 10.1046/j.1524-4741.2003.09406.x.
Sabel MS, Schott AF, Kleer CG, et al: Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg. 2003, 186: 102-105. 10.1016/S0002-9610(03)00168-5.